Adjuvant β-lactam therapy combined with vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Does β-lactam class matter?
Adjuvant β-lactam therapy combined with vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: Does β-lactam class matter?
Antimicrob Agents Chemother. 2019 Jan 07;:
Authors: Dilworth TJ, Casapao AM, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC
Abstract
We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (COMBO) on persistent methicillin-resistant Staphylococcus aureus bacteremia (≥5 days) compared to VAN using pooled data from two previously published, observational studies (n=156). COMBO was inversely associated with persistent bacteremia (adjusted odds ratio 0.460, 95% confidence interval, 0.229-0.923). Acute kidney injury was more common in COMBO than VAN (18.9% and 7.6%, respectively; p=0.062).
PMID: 30617094 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Dilworth TJ, Casapao AM, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC Tags: Antimicrob Agents Chemother Source Type: research
More News: Chemotherapy | Infectious Diseases | Microbiology | MRSA | Staphylococcus Aureus | Study | Superbugs | Urology & Nephrology